Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma

Asher Chanan-Khan, Ruben Niesvizky, Raymond Hohl, Todd M. Zimmerman, Neal P. Christiansen, Gary J. Schiller, Natalie Callander, John Lister, Martin Oken, Sundar Jagannath

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Upregulation of the Bcl-2 antiapoptotic protein is reported to be associated with aggressive clinical course in multiple myeloma. Oblimersen sodium is a bcl-2 antisense oligonucleotide complementary to the first six codons of the open-reading frame of bcl-2 mRNA that can decrease transcription of Bcl-2 protein and increase myeloma cell susceptibility to cytotoxic agents. In this phase III randomised trial, we investigated in patients with relapsed/refractory myeloma whether addition of oblimersen to dexamethasone improved clinical outcomes vs. dexamethasone alone. Two hundred and twenty-four patients were randomised to receive either oblimersen/dexamethasone (N = 110) or dexamethasone alone (N = 114). The primary endpoint was time to tumor progression (TTP). Final results of this study demonstrated no significant differences between the two groups in TTP or objective response rate. The oblimersen/dexamethasone regimen was generally well tolerated with fatigue, fever and nausea, the most common adverse events reported.

Original languageEnglish (US)
Pages (from-to)559-565
Number of pages7
JournalLeukemia and Lymphoma
Volume50
Issue number4
DOIs
StatePublished - Aug 17 2009

Fingerprint

Multiple Myeloma
Dexamethasone
Myeloma Proteins
Antisense Oligonucleotides
Cytotoxins
Codon
Nausea
Open Reading Frames
Fatigue
Neoplasms
Fever
Up-Regulation
oblimersen
Messenger RNA
Proteins

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Chanan-Khan, A., Niesvizky, R., Hohl, R., Zimmerman, T. M., Christiansen, N. P., Schiller, G. J., ... Jagannath, S. (2009). Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leukemia and Lymphoma, 50(4), 559-565. https://doi.org/10.1080/10428190902748971
Chanan-Khan, Asher ; Niesvizky, Ruben ; Hohl, Raymond ; Zimmerman, Todd M. ; Christiansen, Neal P. ; Schiller, Gary J. ; Callander, Natalie ; Lister, John ; Oken, Martin ; Jagannath, Sundar. / Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. In: Leukemia and Lymphoma. 2009 ; Vol. 50, No. 4. pp. 559-565.
@article{216e085c55db4a989b5ee711f1e0c110,
title = "Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma",
abstract = "Upregulation of the Bcl-2 antiapoptotic protein is reported to be associated with aggressive clinical course in multiple myeloma. Oblimersen sodium is a bcl-2 antisense oligonucleotide complementary to the first six codons of the open-reading frame of bcl-2 mRNA that can decrease transcription of Bcl-2 protein and increase myeloma cell susceptibility to cytotoxic agents. In this phase III randomised trial, we investigated in patients with relapsed/refractory myeloma whether addition of oblimersen to dexamethasone improved clinical outcomes vs. dexamethasone alone. Two hundred and twenty-four patients were randomised to receive either oblimersen/dexamethasone (N = 110) or dexamethasone alone (N = 114). The primary endpoint was time to tumor progression (TTP). Final results of this study demonstrated no significant differences between the two groups in TTP or objective response rate. The oblimersen/dexamethasone regimen was generally well tolerated with fatigue, fever and nausea, the most common adverse events reported.",
author = "Asher Chanan-Khan and Ruben Niesvizky and Raymond Hohl and Zimmerman, {Todd M.} and Christiansen, {Neal P.} and Schiller, {Gary J.} and Natalie Callander and John Lister and Martin Oken and Sundar Jagannath",
year = "2009",
month = "8",
day = "17",
doi = "10.1080/10428190902748971",
language = "English (US)",
volume = "50",
pages = "559--565",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "4",

}

Chanan-Khan, A, Niesvizky, R, Hohl, R, Zimmerman, TM, Christiansen, NP, Schiller, GJ, Callander, N, Lister, J, Oken, M & Jagannath, S 2009, 'Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma', Leukemia and Lymphoma, vol. 50, no. 4, pp. 559-565. https://doi.org/10.1080/10428190902748971

Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. / Chanan-Khan, Asher; Niesvizky, Ruben; Hohl, Raymond; Zimmerman, Todd M.; Christiansen, Neal P.; Schiller, Gary J.; Callander, Natalie; Lister, John; Oken, Martin; Jagannath, Sundar.

In: Leukemia and Lymphoma, Vol. 50, No. 4, 17.08.2009, p. 559-565.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma

AU - Chanan-Khan, Asher

AU - Niesvizky, Ruben

AU - Hohl, Raymond

AU - Zimmerman, Todd M.

AU - Christiansen, Neal P.

AU - Schiller, Gary J.

AU - Callander, Natalie

AU - Lister, John

AU - Oken, Martin

AU - Jagannath, Sundar

PY - 2009/8/17

Y1 - 2009/8/17

N2 - Upregulation of the Bcl-2 antiapoptotic protein is reported to be associated with aggressive clinical course in multiple myeloma. Oblimersen sodium is a bcl-2 antisense oligonucleotide complementary to the first six codons of the open-reading frame of bcl-2 mRNA that can decrease transcription of Bcl-2 protein and increase myeloma cell susceptibility to cytotoxic agents. In this phase III randomised trial, we investigated in patients with relapsed/refractory myeloma whether addition of oblimersen to dexamethasone improved clinical outcomes vs. dexamethasone alone. Two hundred and twenty-four patients were randomised to receive either oblimersen/dexamethasone (N = 110) or dexamethasone alone (N = 114). The primary endpoint was time to tumor progression (TTP). Final results of this study demonstrated no significant differences between the two groups in TTP or objective response rate. The oblimersen/dexamethasone regimen was generally well tolerated with fatigue, fever and nausea, the most common adverse events reported.

AB - Upregulation of the Bcl-2 antiapoptotic protein is reported to be associated with aggressive clinical course in multiple myeloma. Oblimersen sodium is a bcl-2 antisense oligonucleotide complementary to the first six codons of the open-reading frame of bcl-2 mRNA that can decrease transcription of Bcl-2 protein and increase myeloma cell susceptibility to cytotoxic agents. In this phase III randomised trial, we investigated in patients with relapsed/refractory myeloma whether addition of oblimersen to dexamethasone improved clinical outcomes vs. dexamethasone alone. Two hundred and twenty-four patients were randomised to receive either oblimersen/dexamethasone (N = 110) or dexamethasone alone (N = 114). The primary endpoint was time to tumor progression (TTP). Final results of this study demonstrated no significant differences between the two groups in TTP or objective response rate. The oblimersen/dexamethasone regimen was generally well tolerated with fatigue, fever and nausea, the most common adverse events reported.

UR - http://www.scopus.com/inward/record.url?scp=68449085118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68449085118&partnerID=8YFLogxK

U2 - 10.1080/10428190902748971

DO - 10.1080/10428190902748971

M3 - Article

C2 - 19373653

AN - SCOPUS:68449085118

VL - 50

SP - 559

EP - 565

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 4

ER -